XELOX + Bevacizumab compared to FOLFOX4 + Bevacizumab in First line Metastatic Colorectal Cancer in a Non-reimbursed Health Care System: A Cost Analysis
Jerry Y. Tan Chun Bing, Andrew A. Yacat, Dennis L. Sacdalan
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
Jerry Y. Tan Chun Bing, Andrew A. Yacat, Dennis L. Sacdalan. "XELOX + Bevacizumab compared to FOLFOX4 + Bevacizumab in First line Metastatic Colorectal Cancer in a Non-reimbursed Health Care System: A Cost Analysis." Acta medica Philippina (2015)